Please assess the completion status of the following clinical trial:

Trial Title: An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Written ICF signed voluntarily before the first trial related activity.~2. Subjects with a history of GERD symptoms (i.e., heartburn and/or regurgitation) during the last 6 months~3. Subjects on a stable dose of PPIs, compliant for at least 6 weeks prior to screening.~4. ≥3 days per week with heartburn and/or regurgitation symptoms of at least moderate severity and a minimum of 25 liquid containing reflux events over 24h (pH/MII monitoring).~Exclusion criteria:~1. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects with major GI disorders.~2. Presence of severe and clinically uncontrolled cardiovascular, liver or lung disease, neurologic, cancer or AIDS.~3. Alarm symptoms suggestive of malignancies or organic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SPD557 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).